Home › Takeda Licenses Rights To Use ImmunoGen, Inc.'s Novel Antibody-Drug Conjugate Technology
 

Keywords :   


Takeda Licenses Rights To Use ImmunoGen, Inc.'s Novel Antibody-Drug Conjugate Technology

2015-04-01 08:41:48| drugdiscoveryonline Home Page

Takeda Pharmaceutical Company Limited and ImmunoGen, Inc., a biotechnology company that develops targeted anticancer therapeutics using its state-of-the-art antibody-drug conjugate (ADC) technology, recently announced that Takeda has licensed exclusive rights to use ImmunoGen’s ADC technology – including ImmunoGen’s new DNA-acting IGN payload agents – to develop and commercialize targeted anticancer therapeutics to up to two undisclosed targets

Tags: rights technology licenses conjugate

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.09Hurricane Isaac Graphics
29.09Tropical Storm Joyce Graphics
29.09Hurricane Isaac Forecast Discussion Number 14
29.09Tropical Storm Joyce Forecast Discussion Number 8
29.09Hurricane Isaac Public Advisory Number 14
29.09Summary for Hurricane Isaac (AT5/AL102024)
29.09Tropical Storm Joyce Wind Speed Probabilities Number 8
29.09Tropical Storm Joyce Public Advisory Number 8
More »